RSS
5 Nov 2026

Acepodia Announces First Patient Dosed in Phase 1 Trial of ACE723, a Novel Dual-Payload Antibody-Drug Conjugate

Author: admintech | Filed under: Press Release

ACE723 is the first candidate from Acepodia’s AD2C platform to enter human testing ALAMEDA, Calif., and TAIPEI, Nov. 5, 2026 /PRNewswire/ — Acepodia (6976: TT), a clinical-stage biotechnology company developing next-generation cell therapies and antibody-drug conjugates, today announced…

This entry was posted on Thursday, November 5th, 2026 at 2:17 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«